Landec Cp (LNDC) 12.66 $LNDC Landec Corporation
Post# of 273254
Posted On: 09/20/2016 5:20:55 AM
Landec Cp (LNDC) 12.66 $LNDC
Landec Corporation Sets First Quarter Fiscal Year 2017 Conference Call for September 28, 2016 at 8 a.m. PT and Earnings Release set for September 27, 2016 After Market
GlobeNewswire - Tue Sep 06, 8:15AM CDT
Landec Corporation (Nasdaq:LNDC) will hold a conference call on Wednesday, September 28, 2016 at 8 a.m. Pacific time to discuss its results for the first quarter fiscal 2017. Financial results will be reported for the 2017 fiscal first quarter ended August 28, 2016 after market close on September 27, 2016.
LNDC: 12.66 (-0.05)
Landec to Present at the 36th Annual Piper Jaffray Consumer Conference on June 14, 2016
GlobeNewswire - Thu Jun 09, 8:15AM CDT
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, has been invited to present at the 36th Annual Piper Jaffray Consumer Conference being held on June 14-15, 2016 at The Lotte New York Palace in New York City.
LNDC: 12.66 (-0.05)
International Flavors & Fragrances (IFF) Q1 Earnings Peek
Zacks Equity Research - Zacks Investment Research - Thu May 05, 6:24AM CDT
International Flavors & Fragrances Inc. (IFF) is scheduled to report first-quarter 2016 results on May 9 after the market close. The Zacks Consensus Estimate for the quarter is $1.41 per share.
IFF: 137.79 (+1.94), LNDC: 12.66 (-0.05), KRA: 33.81 (+0.04), GPRE: 24.94 (+0.25)
Landec Announces BreatheWay Commercial Application with Juicero
GlobeNewswire - Tue May 03, 8:15AM CDT
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, announces that Juicero, Inc., introducer of the first at-home countertop cold-press juicing system, is using BreatheWay(R) in produce packs that deliver fresh-cut fruits and vegetables to Juicero customers.
LNDC: 12.66 (-0.05)
Upgrade Alert for Landec (LNDC)
Comtex SmarTrend(R) - Tue Jan 26, 7:46AM CST
Landec (NASDAQ:LNDC) was upgraded from Neutral to Buy at Sidoti today. The stock closed yesterday at $11.14 on volume of 126,000 shares, below average daily volume of 135,000. Landec (NASDAQ:LNDC) has potential upside of 50.4% based on a current price of $11.14 and analysts' consensus price target of $16.75. The stock should run into initial resistance at its 50-day moving average (MA) of $11.95 and subsequent resistance at its 200-day MA of $13.11.
LNDC: 12.66 (-0.05)
Landec Down 21.1% Since SmarTrend Downtrend Call (LNDC)
Comtex SmarTrend(R) - Thu Jan 21, 5:32PM CST
SmarTrend identified a Downtrend for Landec (NASDAQ:LNDC) on July 23rd, 2015 at $13.49. In approximately 6 months, Landec has returned 21.13% as of today's recent price of $10.64.
LNDC: 12.66 (-0.05)
Landec Down 17.6% Since SmarTrend Downtrend Call (LNDC)
Comtex SmarTrend(R) - Thu Jan 14, 4:20PM CST
SmarTrend identified a Downtrend for Landec (NASDAQ:LNDC) on July 23rd, 2015 at $13.49. In approximately 6 months, Landec has returned 17.57% as of today's recent price of $11.12.
LNDC: 12.66 (-0.05)
Landec tops 2Q profit forecasts
Automated Insights - Tue Jan 05, 3:22PM CST
MENLO PARK, Calif. (AP) _ Landec Corp. (LNDC) on Tuesday reported fiscal second-quarter profit of $1.9 million.
LNDC: 12.66 (-0.05)
Landec Corporation Reports Second Quarter and First Half Fiscal 2016 Results
GlobeNewswire - Tue Jan 05, 3:11PM CST
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, reported results for the second quarter of fiscal 2016 and first six months ended November 29, 2015.
LNDC: 12.66 (-0.05)
9.9% Return Seen to Date on SmarTrend Landec Call (LNDC)
Comtex SmarTrend(R) - Thu Dec 31, 2:24PM CST
SmarTrend identified a Downtrend for Landec (NASDAQ:LNDC) on July 23rd, 2015 at $13.49. In approximately 5 months, Landec has returned 9.86% as of today's recent price of $12.16.
LNDC: 12.66 (-0.05)
Global Orthopedic Biomaterial Market Report - Analysis, Technologies, Materials & Forecasts
M2 - Thu Dec 31, 6:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxpg3x/global_orthopedic) has announced the addition of the "Global Orthopedic Biomaterial Market" report to their offering. Orthopedics is one of the most prominent applications of biomaterials. Orthopedic biomaterials are being increasingly used for treating various musculoskeletal and joint related disorders. This upsurge in the demand of orthopedic biomaterials is driven by augmenting hip and knee replacement surgeries, growing geriatric population, and rising aging population. Furthermore, rising awareness regarding orthopedic disorders and its treatment has also propelled the demand of orthopedic biomaterials. Moreover, citing the demand and potentials of orthopedic biomaterials, the governments of various countries are also providing funds and grants for developing new and advanced biomaterials. However, rising failure of joint implants and high cost of production of biomaterials are some factors which can hinder the growth of the market up to some extent. Metals are most widely used orthopedic biomaterial and find wide application in arthroplasty and fracture fixation devices. However, ceramics, polymers, and orthobiologics segments are poised to witness high double digit growth in the coming five years. The report provides comprehensive view about the orthopedic biomaterials market. The reports includes four types of biomaterials: Metals - Stainless Steel - Titanium Alloy - Cobalt and Chromium Alloys - Precious Metals - Medical Ceramics Alumina - Zirconium dioxide - Calcium Phosphate - Calcium Sulphate - Carbon - Bioactive Glass Ceramics - Medical Polymers Polyethylene - Polymethylmethacrylate (PMMA) - Silicone - Polyester - Polyetheretherketone (PEEK) Natural Biomaterials - Collagen - Chitin & Chitosan - Hyaluronic Acid - Orthobiologics - Demineralised Bone Matrix (DBM) - Growth Factor Proteins - Bone Morphogenetic Proteins - Stem Cells Companies Mentioned: - Carpenter Technology Corporation - Ceramtec - Collagen Matrix, Inc. - DSM N.V - Heraeus Medical Components, Inc - Landec Corporation - Materion Corporation - Purac Biomaterials - Sigma Aldrich - Ulbrich Stainless Steels & Special Metals, Inc. Report Structure: 1 Introduction 2 Research Methodology 3 Report Excerpt 4 Forecast Indicators 5 Market Analysis 6 Orthopedic Biomaterials Market, By Type 7 Orthopedic Biomaterials Market, By Application 8 Geographical Exploration 9 Competitive Analysis 10 Company Profiles 11 Appendix For more information visit http://www.researchandmarkets.com/research/kx...orthopedic
CRS: 37.11 (+1.20), LNDC: 12.66 (-0.05), MTRN: 30.30 (+0.75)
Traders Look to Upside - Comprehensive Research on CAI International, Landec, Guidance Software and Kimball Electronics
ACCESSWIRE - Thu Dec 17, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / December 17, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CAI International Inc (NYSE: CAI), Landec Corporation (NASDAQ: LNDC), Guidance Software, Inc. (NASDAQ: GUID) and Kimball Electronics Inc (NASDAQ: KE). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
GUID: 5.72 (-0.04), LNDC: 12.66 (-0.05), CAI: 8.29 (-0.09), KE: 12.30 (+0.36)
Landec Corporation Sets Second Quarter Fiscal Year 2016 Conference Call for January 6, 2016 at 8 a.m. PT and Earnings Release Set for January 5, 2016 After Market
GlobeNewswire - Tue Dec 15, 9:24AM CST
Landec Corporation (Nasdaq:LNDC) will hold a conference call on Wednesday, January 6, 2016 at 8 a.m. Pacific time to discuss its results for the second quarter fiscal 2016. Financial results will be reported for the 2016 fiscal second quarter ended November 29, 2015 after market close on January 5, 2016.
LNDC: 12.66 (-0.05)
Downtrend Call Working As Landec Stock Falls 11.3% (LNDC)
Comtex SmarTrend(R) - Thu Dec 10, 10:15AM CST
SmarTrend identified a Downtrend for Landec (NASDAQ:LNDC) on July 23rd, 2015 at $13.49. In approximately 5 months, Landec has returned 11.27% as of today's recent price of $11.97.
LNDC: 12.66 (-0.05)
Landec (LNDC) in Focus: Stock Tumbles 6.5%
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 7:48AM CST
Landec saw a big move last session and the stock gained about 6% from Nov 19 to Dec 7, before it slumped nearly 7% yesterday
LNDC: 12.66 (-0.05), RYAM: 11.69 (+0.12)
Downgrade Alert for Landec (LNDC)
Comtex SmarTrend(R) - Wed Dec 09, 7:09AM CST
Landec (NASDAQ:LNDC) was downgraded from Buy to Hold at Feltl today. The stock closed yesterday at $12.17 on volume of 631,000 shares, above average daily volume of 68,000. In the past 52 weeks, Landec share prices have been bracketed by a low of $11.02 and a high of $15.16 and closed yesterday at $12.17, 10% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.2% while the 200-day MA has slid 0.2%.
LNDC: 12.66 (-0.05)
Landec Corporation Revises Guidance for Second Quarter and Fiscal 2016
GlobeNewswire - Tue Dec 08, 5:30AM CST
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, has revised its revenue and net income guidance for the fiscal second quarter and fiscal year 2016 due to severe shortages of key produce items caused by unseasonably warm weather during the second quarter ended November 29, 2015.
LNDC: 12.66 (-0.05)
Landec to Present at the Wedbush Securities California Dreamin' Conference on December 9, 2015
GlobeNewswire - Mon Nov 30, 7:30AM CST
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, has been invited to present at the Wedbush Securities California Dreamin' Management Access Conference. The conference is being held on December 9-10, 2015 at the Loews Santa Monica Hotel in Santa Monica, CA.
LNDC: 12.66 (-0.05)
Global Orthopedic Biomaterials Market 2015-2021 - Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation and Forecasts
M2 - Mon Nov 16, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/bw2mc6/global_orthopedic) has announced the addition of the "Global Orthopedic Biomaterials Market by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation and Forecast 2015 - 2021" report to their offering. Orthopaedic biomaterials market is expected to grow at a CAGR of 11% for the forecasted period of 2015-2021 The market is segmented on the basis of products, application and biomaterials type. The biomaterials type includes metals and non-metals. Metals include stainless steel, titanium and cobalt alloys; non metals include ceramics, polymers and composites. Application of biomaterials includes orthobiologics, joint replacements, viscosupplementation and others. Products include bone allografts, aligned bone matrix, machined bones, bone morphogenetic protein, synthetic bone substitute and others. The market is driven by high expenditure in the research and development field. New biomaterials are being developed which are more compatible to human body. One of the major issues faced by manufacturers, physicians and patients alike is the biocompatibility of the products. Manufacturers are working on various new biomaterials and developing tissue reengineering techniques. Polymer based biodegradable biomaterials are being produced at a higher volume such as polyglycolic acid and polylactic acids. These polymers can easily be placed, as the implants are removed the callus strength increases. The hardware removal is not necessary therefore reducing the cost. High prevalence of age related lifestyle diseases and increasing number of elderly population is also driving the market. The market is highly competitive and consists of some major player such as Genzyme Corporation, Carpenter Technology Corporation, and Materion Corporation. Ulbrich Stainless Steel & Special Metals, Inc., Heraeus Medical Components, CeramTec (a subsidiary of Rockwood Holdings Inc.), Ceradyne, Inc., Kyocera Corporation, Bayer, Purac Biomaterials and others. Key Topics Covered: 1. Introduction 2. Market Overview 3. Market Determinants 4. Sector Analysis 5. Market Segmentation 6. Competitive Landscape 7. Geographical Analysis 8. Company Profiles - Bayer - Biocoat Incorporated - Biocomposites Ltd - Biomet - Cam Bioceramics BV - Carpenter Technology Corporation - Ceradyne, Inc - CeramTec (a subsidiary of Rockwood Holdings Inc) - Collagen Matrix Inc - DePuy Synthes - DSM Biomedical Inc - Etex Corp - Evonik Industries AG - Genzyme Corporation - Heraeus Medical Components - Integra lifesciences Inc - Invibo PEEK biomaterial solutions - Kyocera Corporation - Materion Corporation - Medtronic - NovaBone Products LLC - Osteotech, Inc - Purac Biomaterials - Starch Medical, Inc Landec Corporation - Stryker - Ticona GmbH - Ulbrich Stainless Steel & Special Metals, Inc - Wright Medical Group - Zimmer Holdings For more information visit http://www.researchandmarkets.com/research/bw...orthopedic
ZMH: 113.56 (+0.29), KYO: 48.36 (+0.41), CRS: 37.11 (+1.20), MDT: 85.99 (-0.02), LNDC: 12.66 (-0.05), ROC: 79.20 (+0.33), WMGIZ: 1.35 (unch), MTRN: 30.30 (+0.75)
Landec Corporation Sets First Quarter Fiscal Year 2017 Conference Call for September 28, 2016 at 8 a.m. PT and Earnings Release set for September 27, 2016 After Market
GlobeNewswire - Tue Sep 06, 8:15AM CDT
Landec Corporation (Nasdaq:LNDC) will hold a conference call on Wednesday, September 28, 2016 at 8 a.m. Pacific time to discuss its results for the first quarter fiscal 2017. Financial results will be reported for the 2017 fiscal first quarter ended August 28, 2016 after market close on September 27, 2016.
LNDC: 12.66 (-0.05)
Landec to Present at the 36th Annual Piper Jaffray Consumer Conference on June 14, 2016
GlobeNewswire - Thu Jun 09, 8:15AM CDT
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, has been invited to present at the 36th Annual Piper Jaffray Consumer Conference being held on June 14-15, 2016 at The Lotte New York Palace in New York City.
LNDC: 12.66 (-0.05)
International Flavors & Fragrances (IFF) Q1 Earnings Peek
Zacks Equity Research - Zacks Investment Research - Thu May 05, 6:24AM CDT
International Flavors & Fragrances Inc. (IFF) is scheduled to report first-quarter 2016 results on May 9 after the market close. The Zacks Consensus Estimate for the quarter is $1.41 per share.
IFF: 137.79 (+1.94), LNDC: 12.66 (-0.05), KRA: 33.81 (+0.04), GPRE: 24.94 (+0.25)
Landec Announces BreatheWay Commercial Application with Juicero
GlobeNewswire - Tue May 03, 8:15AM CDT
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, announces that Juicero, Inc., introducer of the first at-home countertop cold-press juicing system, is using BreatheWay(R) in produce packs that deliver fresh-cut fruits and vegetables to Juicero customers.
LNDC: 12.66 (-0.05)
Upgrade Alert for Landec (LNDC)
Comtex SmarTrend(R) - Tue Jan 26, 7:46AM CST
Landec (NASDAQ:LNDC) was upgraded from Neutral to Buy at Sidoti today. The stock closed yesterday at $11.14 on volume of 126,000 shares, below average daily volume of 135,000. Landec (NASDAQ:LNDC) has potential upside of 50.4% based on a current price of $11.14 and analysts' consensus price target of $16.75. The stock should run into initial resistance at its 50-day moving average (MA) of $11.95 and subsequent resistance at its 200-day MA of $13.11.
LNDC: 12.66 (-0.05)
Landec Down 21.1% Since SmarTrend Downtrend Call (LNDC)
Comtex SmarTrend(R) - Thu Jan 21, 5:32PM CST
SmarTrend identified a Downtrend for Landec (NASDAQ:LNDC) on July 23rd, 2015 at $13.49. In approximately 6 months, Landec has returned 21.13% as of today's recent price of $10.64.
LNDC: 12.66 (-0.05)
Landec Down 17.6% Since SmarTrend Downtrend Call (LNDC)
Comtex SmarTrend(R) - Thu Jan 14, 4:20PM CST
SmarTrend identified a Downtrend for Landec (NASDAQ:LNDC) on July 23rd, 2015 at $13.49. In approximately 6 months, Landec has returned 17.57% as of today's recent price of $11.12.
LNDC: 12.66 (-0.05)
Landec tops 2Q profit forecasts
Automated Insights - Tue Jan 05, 3:22PM CST
MENLO PARK, Calif. (AP) _ Landec Corp. (LNDC) on Tuesday reported fiscal second-quarter profit of $1.9 million.
LNDC: 12.66 (-0.05)
Landec Corporation Reports Second Quarter and First Half Fiscal 2016 Results
GlobeNewswire - Tue Jan 05, 3:11PM CST
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, reported results for the second quarter of fiscal 2016 and first six months ended November 29, 2015.
LNDC: 12.66 (-0.05)
9.9% Return Seen to Date on SmarTrend Landec Call (LNDC)
Comtex SmarTrend(R) - Thu Dec 31, 2:24PM CST
SmarTrend identified a Downtrend for Landec (NASDAQ:LNDC) on July 23rd, 2015 at $13.49. In approximately 5 months, Landec has returned 9.86% as of today's recent price of $12.16.
LNDC: 12.66 (-0.05)
Global Orthopedic Biomaterial Market Report - Analysis, Technologies, Materials & Forecasts
M2 - Thu Dec 31, 6:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxpg3x/global_orthopedic) has announced the addition of the "Global Orthopedic Biomaterial Market" report to their offering. Orthopedics is one of the most prominent applications of biomaterials. Orthopedic biomaterials are being increasingly used for treating various musculoskeletal and joint related disorders. This upsurge in the demand of orthopedic biomaterials is driven by augmenting hip and knee replacement surgeries, growing geriatric population, and rising aging population. Furthermore, rising awareness regarding orthopedic disorders and its treatment has also propelled the demand of orthopedic biomaterials. Moreover, citing the demand and potentials of orthopedic biomaterials, the governments of various countries are also providing funds and grants for developing new and advanced biomaterials. However, rising failure of joint implants and high cost of production of biomaterials are some factors which can hinder the growth of the market up to some extent. Metals are most widely used orthopedic biomaterial and find wide application in arthroplasty and fracture fixation devices. However, ceramics, polymers, and orthobiologics segments are poised to witness high double digit growth in the coming five years. The report provides comprehensive view about the orthopedic biomaterials market. The reports includes four types of biomaterials: Metals - Stainless Steel - Titanium Alloy - Cobalt and Chromium Alloys - Precious Metals - Medical Ceramics Alumina - Zirconium dioxide - Calcium Phosphate - Calcium Sulphate - Carbon - Bioactive Glass Ceramics - Medical Polymers Polyethylene - Polymethylmethacrylate (PMMA) - Silicone - Polyester - Polyetheretherketone (PEEK) Natural Biomaterials - Collagen - Chitin & Chitosan - Hyaluronic Acid - Orthobiologics - Demineralised Bone Matrix (DBM) - Growth Factor Proteins - Bone Morphogenetic Proteins - Stem Cells Companies Mentioned: - Carpenter Technology Corporation - Ceramtec - Collagen Matrix, Inc. - DSM N.V - Heraeus Medical Components, Inc - Landec Corporation - Materion Corporation - Purac Biomaterials - Sigma Aldrich - Ulbrich Stainless Steels & Special Metals, Inc. Report Structure: 1 Introduction 2 Research Methodology 3 Report Excerpt 4 Forecast Indicators 5 Market Analysis 6 Orthopedic Biomaterials Market, By Type 7 Orthopedic Biomaterials Market, By Application 8 Geographical Exploration 9 Competitive Analysis 10 Company Profiles 11 Appendix For more information visit http://www.researchandmarkets.com/research/kx...orthopedic
CRS: 37.11 (+1.20), LNDC: 12.66 (-0.05), MTRN: 30.30 (+0.75)
Traders Look to Upside - Comprehensive Research on CAI International, Landec, Guidance Software and Kimball Electronics
ACCESSWIRE - Thu Dec 17, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / December 17, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CAI International Inc (NYSE: CAI), Landec Corporation (NASDAQ: LNDC), Guidance Software, Inc. (NASDAQ: GUID) and Kimball Electronics Inc (NASDAQ: KE). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
GUID: 5.72 (-0.04), LNDC: 12.66 (-0.05), CAI: 8.29 (-0.09), KE: 12.30 (+0.36)
Landec Corporation Sets Second Quarter Fiscal Year 2016 Conference Call for January 6, 2016 at 8 a.m. PT and Earnings Release Set for January 5, 2016 After Market
GlobeNewswire - Tue Dec 15, 9:24AM CST
Landec Corporation (Nasdaq:LNDC) will hold a conference call on Wednesday, January 6, 2016 at 8 a.m. Pacific time to discuss its results for the second quarter fiscal 2016. Financial results will be reported for the 2016 fiscal second quarter ended November 29, 2015 after market close on January 5, 2016.
LNDC: 12.66 (-0.05)
Downtrend Call Working As Landec Stock Falls 11.3% (LNDC)
Comtex SmarTrend(R) - Thu Dec 10, 10:15AM CST
SmarTrend identified a Downtrend for Landec (NASDAQ:LNDC) on July 23rd, 2015 at $13.49. In approximately 5 months, Landec has returned 11.27% as of today's recent price of $11.97.
LNDC: 12.66 (-0.05)
Landec (LNDC) in Focus: Stock Tumbles 6.5%
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 7:48AM CST
Landec saw a big move last session and the stock gained about 6% from Nov 19 to Dec 7, before it slumped nearly 7% yesterday
LNDC: 12.66 (-0.05), RYAM: 11.69 (+0.12)
Downgrade Alert for Landec (LNDC)
Comtex SmarTrend(R) - Wed Dec 09, 7:09AM CST
Landec (NASDAQ:LNDC) was downgraded from Buy to Hold at Feltl today. The stock closed yesterday at $12.17 on volume of 631,000 shares, above average daily volume of 68,000. In the past 52 weeks, Landec share prices have been bracketed by a low of $11.02 and a high of $15.16 and closed yesterday at $12.17, 10% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.2% while the 200-day MA has slid 0.2%.
LNDC: 12.66 (-0.05)
Landec Corporation Revises Guidance for Second Quarter and Fiscal 2016
GlobeNewswire - Tue Dec 08, 5:30AM CST
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, has revised its revenue and net income guidance for the fiscal second quarter and fiscal year 2016 due to severe shortages of key produce items caused by unseasonably warm weather during the second quarter ended November 29, 2015.
LNDC: 12.66 (-0.05)
Landec to Present at the Wedbush Securities California Dreamin' Conference on December 9, 2015
GlobeNewswire - Mon Nov 30, 7:30AM CST
Landec Corporation (NASDAQ:LNDC), a leading developer and marketer of innovative and proprietary products for healthy living applications in the food and biomedical markets, has been invited to present at the Wedbush Securities California Dreamin' Management Access Conference. The conference is being held on December 9-10, 2015 at the Loews Santa Monica Hotel in Santa Monica, CA.
LNDC: 12.66 (-0.05)
Global Orthopedic Biomaterials Market 2015-2021 - Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation and Forecasts
M2 - Mon Nov 16, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/bw2mc6/global_orthopedic) has announced the addition of the "Global Orthopedic Biomaterials Market by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Trends, Analysis, Opportunities, Segmentation and Forecast 2015 - 2021" report to their offering. Orthopaedic biomaterials market is expected to grow at a CAGR of 11% for the forecasted period of 2015-2021 The market is segmented on the basis of products, application and biomaterials type. The biomaterials type includes metals and non-metals. Metals include stainless steel, titanium and cobalt alloys; non metals include ceramics, polymers and composites. Application of biomaterials includes orthobiologics, joint replacements, viscosupplementation and others. Products include bone allografts, aligned bone matrix, machined bones, bone morphogenetic protein, synthetic bone substitute and others. The market is driven by high expenditure in the research and development field. New biomaterials are being developed which are more compatible to human body. One of the major issues faced by manufacturers, physicians and patients alike is the biocompatibility of the products. Manufacturers are working on various new biomaterials and developing tissue reengineering techniques. Polymer based biodegradable biomaterials are being produced at a higher volume such as polyglycolic acid and polylactic acids. These polymers can easily be placed, as the implants are removed the callus strength increases. The hardware removal is not necessary therefore reducing the cost. High prevalence of age related lifestyle diseases and increasing number of elderly population is also driving the market. The market is highly competitive and consists of some major player such as Genzyme Corporation, Carpenter Technology Corporation, and Materion Corporation. Ulbrich Stainless Steel & Special Metals, Inc., Heraeus Medical Components, CeramTec (a subsidiary of Rockwood Holdings Inc.), Ceradyne, Inc., Kyocera Corporation, Bayer, Purac Biomaterials and others. Key Topics Covered: 1. Introduction 2. Market Overview 3. Market Determinants 4. Sector Analysis 5. Market Segmentation 6. Competitive Landscape 7. Geographical Analysis 8. Company Profiles - Bayer - Biocoat Incorporated - Biocomposites Ltd - Biomet - Cam Bioceramics BV - Carpenter Technology Corporation - Ceradyne, Inc - CeramTec (a subsidiary of Rockwood Holdings Inc) - Collagen Matrix Inc - DePuy Synthes - DSM Biomedical Inc - Etex Corp - Evonik Industries AG - Genzyme Corporation - Heraeus Medical Components - Integra lifesciences Inc - Invibo PEEK biomaterial solutions - Kyocera Corporation - Materion Corporation - Medtronic - NovaBone Products LLC - Osteotech, Inc - Purac Biomaterials - Starch Medical, Inc Landec Corporation - Stryker - Ticona GmbH - Ulbrich Stainless Steel & Special Metals, Inc - Wright Medical Group - Zimmer Holdings For more information visit http://www.researchandmarkets.com/research/bw...orthopedic
ZMH: 113.56 (+0.29), KYO: 48.36 (+0.41), CRS: 37.11 (+1.20), MDT: 85.99 (-0.02), LNDC: 12.66 (-0.05), ROC: 79.20 (+0.33), WMGIZ: 1.35 (unch), MTRN: 30.30 (+0.75)
(0)
(0)Scroll down for more posts ▼